Skip to main content
First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. Ansell, S. M., Connors, J. M., Radford, J. A., Kim, W., Gallamini, A., Ramchandren, R., Friedberg, J. W., Advani, R. H., Hutchings, M., Evens, A. M., Smolewski, P., Savage, K. J., Bartlett, N. L., Eom, H., Abramson, J. S., Dong, C., Campana, F., Fenton, K., Puhlmann, M., Straus, D. J. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for Web of Science ID 000863680301966